Harris, Linda
Graham, Sophie
MacLachlan, Sharon
Exuzides, Alex
Jacob, Saiju
Article History
Received: 24 September 2021
Accepted: 25 April 2022
First Online: 9 May 2022
Declarations
:
: Informed consent was not required from all participants included in the study since the data used in the study was fully de-identified and therefore there were no patient identifiers. The ethics committee that waivered the need for informed consent was the Independent Scientific Advisory Committee for Medicines and Healthcare Products Regulatory Agency database research. This committee also approved the conduct of the study (17_111). All authors confirm that the research was conducted in accordance with the Declaration of Helsinki.
: Not applicable.
: LH disclosed that, at the time the study was conducted, she was an employee of Alexion Pharmaceuticals, the study sponsor, and owns shares in the company. SG and SM are current employees of Evidera and AE is a former Evidera employee; Evidera received payment from Alexion Pharmaceuticals for work on this study and for medical writing support. SJ has disclosed that he received honoraria and expenses from Alexion Pharmaceuticals as an international advisory board member for the Eculizumab in Myasthenia trial, has received honoraria and speaker fees from Alnylam pharmaceuticals, Terumo BCT, and Eisai Ltd, and research support from Momenta pharmaceuticals, argenX pharma and UCB Ltd.